Answers are grounded in this paper and cite their sources.
Background: Patent ductus arteriosus (PDA) refers to the continued existence postnatally of the fetal link (ductus arteriosus) connecting the aorta and the pulmonary artery. Objective: determine whether the surfactant replacement therapy used for the treatment of respiratory distress syndrome (RDS) is affecting the incidence and/or the closure of PDA. Also to study the different treatment strategies for RDS and PDA and its effects on the PDA closure in preterm infants. Methods: A prospective observational study done in the neonatal intensive care unit in a tertiary center in Baghdad, Iraq. The study was conducted from July 2024 to February 2025. The patients included in the study are all preterm infants less than 37 weeks' gestational age who were diagnosed with RDS and treated for that by either nasal continuous positive airway pressure (CPAP), mechanical ventilation (MV), or both. Results: 43 preterm infants were included with a median gestational age at labor of 30 (IQR=8-33) weeks; birth weight ranged between 750 and 2250 grams with a median of 1400 grams (IQR=1100-1900). Males were the dominant contributor, accounting for 60.5%. Only 20.9% of infants were breastfed, 46.5% were on formula, and 32.6% received mixed feeding. The closure of PDA occurred in 15 (34.9%) infants, while closure failed (persistent PDA) in 10 (23.3%) and 18 (41.9%) remained with no PDA. Conclusions: There was no difference in the treatment of PDA between infants who received surfactant and those who received respiratory support with NCPAP or MV, despite the increased number of closed PDAs in treated infants; however, there was a significant difference in PDA closure based on whether the infants received treatment.
No takes yet. Share an insight, caveat, or question.
Al-Bermany et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: